Emiliano Chisci’s Post

Join the webinar to explore real-world applications of the next generation ClosureFastᵀᴹ in clinical settings through case studies and scenarios. Seize the opportunity to participate in a live Q&A session with the experts. 🔗 https://ow.ly/SFf850QjQ85

The high demand for PET studies with PSMA for staging and re-staging with PCa limits the availability of this molecularimaging modality to evaluate patients candidates for radioligand Therapy. WB SPECT 99m Tc iPSMA has shown high agreement with WB SPECT 177 Lu iPSMA, with greater availability and lower cost. #molecularimagingMexico #Teragnostics #ININ #prostatecancer #PSMA 🇲🇽 Instituto Nacional de Investigaciones Nucleares

And what would be better than a Veriton SPECT/CT from Spectrum Dynamics Medical to image and quantify 99mTc iPSMA distribution in patients with PCa?

As we hit the #RoadToEurope we’re showcasing the innovators from around the globe who are selected to present at #LSIEurope24. Today we’re showcasing 3 innovators in Israel selected to present at LSI Europe ‘24 in Portugal: 1. Jordan Pollack — VeinWay Ltd. → Its Traversa catheter has been designed to penetrate blockages with its unique features, including: a steerable needle to maintain navigational control, a 6mm balloon that anchors the device to enhance needle penetration, and a braided catheter that balances catheter strength and flexibility. 2. Dr. Ofir Aharon — PATTERNOX → Developed a handheld scanner that can detect lesion distortions, a warning sign of cancer and cosmetic abnormalities. The device does not rely on ubiquitous color change, but on distortions beneath the skin to detect potentially harmful lesions. 3. Ilan Uchitel — CAPS Medical → Developed a proprietary Non-Thermal Plasma technology (NTAPTM) platform that selectively targets a diverse range of tumors, through minimally invasive procedures, while preserving healthy tissue. We look forward to seeing these innovators take the stage this September 16th - 20th in Portugal. Want to see what other innovators are presenting at LSI Europe ‘24? Head over to our website to see the first 100+ innovators selected to present.

Congratulations to Dr. Lauren Ranard, Dr. Yanping C., Dr. Genghua Yi, Dr. Diane Ordanes, Torsten Vahl, Dr. Paolo Denti, Giovanni Righini, Mitchell McBride, John Butziger, Sean Forde for their recent publication in EuroIntervention: Procedural performance and healing response of a novel low-profile transseptal transcatheter mitral valve replacement system. This study assessed the acute and chronic performance of the novel Saturn TMVR system in healthy preclinical models and demonstrated that 1) transseptal delivery of this bioprosthesis is feasible and reproducible and 2) that the valve has excellent haemodynamics with favourable biocompatibility over a 150-day follow-up period in an animal model. The full article is accessible for Eurointervention subscribers here: https://lnkd.in/dtMBG3Wg Saturn is a novel, investigational TMVR system with a 29 French Valve Delivery System and 2 valve sizes (28 and 31mm) designed to anchor through a subannular ring at the base of the left ventricle providing mechanical continuity between the bioprosthesis and the annular segments. The Saturn device aims to minimize patient exclusion due to unsupported annulus size/shape and left ventricle size, and to minimize the risks of valve migration, paravalvular leaks, LVOT obstruction and Systolic Anterior Motion. (Saturn TMVR System is an investigational device only and not for sale in any geography.) #Mitral #TMVR #Saturn #Innovation. Learn more at www.InnovHeart.com

🌟 Sysnav Healthcare is grateful to see Roche presenting a poster on our Syde-derived SV95C at the 21st International Conference on Duchenne and Becker Muscular Dystrophy, hosted by Parent Project aps. Title of the Poster: The Importance and use of Syde® wearable Technology and the Stride Velocity 95th Centile (SV95C) Endpoint in Duchenne muscular dystrophy SV95C is the first digital endpoint to be qualified as a primary endpoint in clinical trials for Duchenne Muscular Dystrophy by a regulatory body (European Medicines Agency). The poster highlights the importance of digital outcome measures and how clinicians and investigators can use them to precisely measure the response of patients to a treatment. This aligns with Sysnav Healthcare's mission to use meaningful real-world data to accelerate medical progress. If you want to learn more about SV95C, you can find the link to the poster in the comments below! #DMD #SV95C #clinicaltrials

Make sure not to miss out on this excellent webinar!

Review the clinical data and real-world experiences presented at the 41st Congress of the ESCRS on Vivinex Gemetric and Vivinex Gemetric Plus IOLs (HOYA Surgical Optics). Erik L. Mertens, MD, FEBO, PCEO, FWCRS, moderated a panel consisting of: Bob Anello; Hakan Kaymak, MD; Ramón Ruiz Mesa, MD, FWCRS; and Dylan A. Joseph, MBChB, Dip(Ophth), FC Ophth, MMed, FWCRS. Read their thoughts on the impressive results in both clinical trials and the real world. #sponsored https://bit.ly/3QGcInD

Pass by if you’re at the Single Cell Conference (SDU)- and have a talk about gentle cell dissociation, gentle cell enrichment prep for #scRNA-seq, sustainable RNA extraction and much more. #NGS #CTSV #LevitasBio #ScaleBio #BioEcho

Radiation dose is elegantly defined as simply a measure of energy absorbed per unit mass. However, calculating the biological impact of radiation on humans can be complicated, as it depends on several factors. Currently, radiopharmaceutical trials are frequently stopped because of conventional dose limitations for organs at risk. However, it's becoming increasingly apparent that these limitations may be too conservative and unsuitable for radiopharmaceutical therapies. This just-published paper in JCO by Ana Kiess et al. highlights this issue. It presents solid recommendations for phase 1 clinical trials, which could be used to establish appropriate tolerances for organs at risk in radiopharmaceutical therapies. This is excellent work by the RTP-TEC group; they have additional important manuscripts in progress. ##teamwork #radiopharmaceuticals #RPT #theranostics Ana Kiess Joe O'Donoghue Carlos UribeLisa Bodei Adam Kesner George Sgouros Society of Nuclear Medicine and Molecular Imaging (SNMMI) European Association of Nuclear Medicine (EANM) American Society for Radiation Oncology American Association of Physicists in Medicine Oncidium foundation